Jan 22, 2009 by Brian Orelli, PhDUnitedHealth Says Good Riddance to 2008Unfortunately, prospects for 2009 don't look much better.
Jan 21, 2009 by Brian Orelli, PhDA Copycat on the ProwlTeva wisely invites another partner to the biosimilar dance.
Jan 21, 2009 by Brian Orelli, PhDPharma Foe Speaks Up for InvestorsDr. Steven Nissen has a smart proposal for Obama's FDA.
Jan 20, 2009 by Brian Orelli, PhDJohnson & Johnson Nimble ... for NowThe health-care giant reports increasing earnings, despite falling revenue.
Jan 16, 2009 by Brian Orelli, PhDSealed Lips Don't Sink ShipsAt the JPMorgan health care conference, there's updates aplenty, but not for the most interesting stories.
Jan 16, 2009 by Brian Orelli, PhDLilly Pays Up. Big Deal.Pharmaceutical investors have to expect these kinds of legal defeats.
Jan 15, 2009 by Brian Orelli, PhDA Clean Bill of Health in 2009UnitedHealth settles a few lawsuits to start the new year.
Jan 14, 2009 by Brian Orelli, PhDZymoGenetics, the Pharmaceutical ZombieA Bristol-Myers deal brings the drug developer stumbling back from the dead.
Jan 14, 2009 by Brian Orelli, PhDFDA's Bipolar Decision on Schering's DrugSigns point to an approval, but there isn't one yet.
Jan 12, 2009 by Brian Orelli, PhDTrust Management or Don't BuyAs George Michael would say, "You gotta have faith."
Jan 9, 2009 by Brian Orelli, PhDAlnylam Holds Hands With a New FellaIs big pharma turning up its nose at RNAi drugs?
Jan 8, 2009 by Brian Orelli, PhDFDA Toys With Lilly, and Investors, AgainEli Lilly will have to wait a little longer.
Jan 7, 2009 by Brian Orelli, PhDA One-Hit Wonder Goes for No. 2Onyx is swinging for the fences again, but it's still in the clubhouse.
Jan 6, 2009 by Brian Orelli, PhDBoston Scientific Gets Gussied UpIt's buying a lab coat -- the company, not the jacket.
